What is the recommended starting dose, monitoring schedule, and side effect management for Ofev (nintedanib) in an adult with idiopathic pulmonary fibrosis who does not have moderate-to-severe hepatic impairment or pregnancy?

Ofev (Nintedanib) Dosing and Management in IPF

The recommended starting dose of Ofev is 150 mg orally twice daily (approximately 12 hours apart) taken with food, with liver function tests monitored before treatment, at regular intervals during the first three months, and periodically thereafter. 1

Starting Dose

• Standard dose: 150 mg twice daily taken with food, approximately 12 hours apart 1
• Mild hepatic impairment (Child Pugh A): 100 mg twice daily 1
• Moderate-to-severe hepatic impairment: Not recommended 1
• Capsules must be swallowed whole with liquid—do not chew, open, or crush 1
• If a dose is missed, take the next dose at the scheduled time; do not double up 1

Monitoring Schedule

Liver Function Tests (Critical)

Monitor ALT, AST, and bilirubin:

• Before initiating treatment 1
• At regular intervals during the first three months of treatment 1
• Periodically thereafter or as clinically indicated 1
• Promptly if symptoms suggest liver injury (fatigue, anorexia, right upper abdominal discomfort, dark urine, jaundice) 1

The majority of hepatic events occur within the first three months, making this monitoring window particularly critical 1. In the postmarketing period, severe drug-induced liver injury with fatal outcomes has been reported 1.

Pregnancy Testing

• Conduct pregnancy test in females of reproductive potential before starting treatment 1

Side Effect Management

Gastrointestinal Effects (Most Common)

Diarrhea is the most frequent adverse event, occurring in approximately 62% of patients 2, 3, 4:

• Treat at first signs with adequate hydration and antidiarrheal medication (e.g., loperamide) 1
• Despite high incidence, only 4.4% of patients discontinued due to diarrhea in clinical trials 3
• Discontinue if severe diarrhea persists despite symptomatic treatment 1

Nausea and vomiting:

• Treat with anti-emetics 1
• Discontinue if severe symptoms persist despite treatment 1

Hepatotoxicity Management Algorithm

For AST/ALT >5× ULN or >3× ULN with signs/symptoms of liver injury:

• Discontinue Ofev permanently 1

For AST/ALT >3× to <5× ULN without signs of liver damage:

• Interrupt treatment or reduce to 100 mg twice daily 1
• Once liver enzymes return to baseline, may reintroduce at 100 mg twice daily 1
• Subsequently may increase back to 150 mg twice daily 1

Liver enzyme elevations were reversible with dose modification in the majority of cases 1.

Dose Reduction Strategy

In clinical trials, 27.9% of patients required dose reduction to 100 mg twice daily and 23.7% required treatment interruption 3:

• First step: Reduce to 100 mg twice daily 1
• If patient does not tolerate 100 mg twice daily, discontinue permanently 1
• After adverse event resolution, may resume at 100 mg twice daily, then potentially increase back to 150 mg twice daily 1

Other Important Adverse Events

Gastrointestinal effects increased with nintedanib 2:

• Abdominal pain (4.2× increase)
• Nausea (3.1× increase)
• Vomiting (3.6× increase)
• Weight loss (3.7× increase)

Cardiovascular: Use caution in patients with known coronary artery disease due to arterial thromboembolic event risk 1

Bleeding: Use only if benefit outweighs risk in patients with known bleeding risk 1

Gastrointestinal perforation: Use with caution in patients with recent abdominal surgery, diverticular disease, or receiving corticosteroids/NSAIDs; discontinue if perforation occurs 1

Proteinuria: Consider treatment interruption if new or worsening proteinuria develops 1

Clinical Context

The 2022 ATS/ERS/JRS/ALAT guidelines provide a conditional recommendation for nintedanib in progressive pulmonary fibrosis (PPF) in patients who have failed standard management for fibrotic ILD other than IPF 2. For IPF specifically, nintedanib is an established antifibrotic therapy that slows disease progression 2.

Common pitfall: The high incidence of diarrhea (>60%) can be alarming, but proactive management with loperamide and hydration allows most patients to continue therapy 3, 4. Early intervention at first signs of GI symptoms is key to preventing treatment discontinuation.

Gender consideration: Females have a 3-4 fold higher exposure-adjusted risk of liver enzyme elevations compared to males, warranting closer monitoring 5.